Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy Jan 17, 2023
Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event Jan 5, 2023
Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform Nov 16, 2022
Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update Nov 10, 2022
Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics Oct 11, 2022
Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board Oct 4, 2022
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference Sep 7, 2022
Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update Aug 12, 2022
Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer Aug 2, 2022
Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study Jul 7, 2022
